143 related articles for article (PubMed ID: 20729709)
1. Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation.
Tosini W; Muller P; Prazuck T; Benabdelmoumen G; Peyrouse E; Christian B; Quertainmont Y; Bouvet E; Rabaud C
AIDS; 2010 Sep; 24(15):2375-80. PubMed ID: 20729709
[TBL] [Abstract][Full Text] [Related]
2. Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
Uy J; Yang R; Wirtz V; Sheppard L; Farajallah A; McGrath D
AIDS Care; 2011 Nov; 23(11):1500-4. PubMed ID: 21732894
[TBL] [Abstract][Full Text] [Related]
3. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
Hill A; Sawyer W
HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
[TBL] [Abstract][Full Text] [Related]
4. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
Chetchotisakd P
Expert Rev Anti Infect Ther; 2009 Sep; 7(7):801-5. PubMed ID: 19735222
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection.
Elion R; Cohen C; Gathe J; Shalit P; Hawkins T; Liu HC; Mathias AA; Chuck SL; Kearney BP; Warren DR;
AIDS; 2011 Sep; 25(15):1881-6. PubMed ID: 21811136
[TBL] [Abstract][Full Text] [Related]
6. Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir.
Gutmann C; Cusini A; Günthard HF; Fux C; Hirschel B; Decosterd LA; Cavassini M; Yerly S; Vernazza PL;
AIDS; 2010 Sep; 24(15):2347-54. PubMed ID: 20802298
[TBL] [Abstract][Full Text] [Related]
7. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
Bickel M; Bodtländer A; Knecht GK; Stephan C; von Hentig N; Kurowski M; Gute P; Klauke S; Lutz T
J Antimicrob Chemother; 2009 Dec; 64(6):1260-4. PubMed ID: 19776037
[TBL] [Abstract][Full Text] [Related]
8. Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.
Huang F; Scholl P; Huang DB; MacGregor TR; Taub ME; Vinisko R; Castles MA; Robinson P
Basic Clin Pharmacol Toxicol; 2011 Mar; 108(3):163-70. PubMed ID: 20977679
[TBL] [Abstract][Full Text] [Related]
9. Lack of evidence for an effect of lopinavir/ritonavir on tenofovir renal clearance.
Ray AS; Wright MR; Rhodes GR
Clin Pharmacol Ther; 2008 Dec; 84(6):660; author reply 661. PubMed ID: 18615003
[No Abstract] [Full Text] [Related]
10. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
11. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
; Arrivé E; Chaix ML; Nerrienet E; Blanche S; Rouzioux C; Coffie PA; Kruy Leang S; McIntyre J; Avit D; Srey VH; Gray G; N'Dri-Yoman T; Diallo A; Ekouévi DK; Dabis F
AIDS; 2009 Apr; 23(7):825-33. PubMed ID: 19307941
[TBL] [Abstract][Full Text] [Related]
12. Maternal and nenonatal tenofovir and emtricitabine to prevent vertical transmission of HIV-1: tolerance and resistance.
; Arrivé E; Chaix ML; Nerrienet E; Blanche S; Rouzioux C; Avit D; Kruy LS; McIntyre J; Say L; Gray G; Ekouévi DK; Dabis F
AIDS; 2010 Oct; 24(16):2481-8. PubMed ID: 20827166
[TBL] [Abstract][Full Text] [Related]
13. Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II).
Parks DA; Jennings HC; Taylor C; Pakes GE; Acosta EP
HIV Clin Trials; 2009; 10(3):160-7. PubMed ID: 19632955
[TBL] [Abstract][Full Text] [Related]
14. Safety, efficacy and development of resistance under the new protease inhibitor lopinavir/ritonavir: 48-week results.
Voigt E; Wasmuth JC; Vogel M; Mauss S; Schmutz G; Kaiser R; Rockstroh JK
Infection; 2004 Apr; 32(2):82-8. PubMed ID: 15057572
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients.
Labarga P; Medrano J; Seclen E; Poveda E; Rodriguez-Novoa S; Morello J; de Mendoza C; Vispo E; Soriano V
AIDS; 2010 Mar; 24(5):777-9. PubMed ID: 20168201
[TBL] [Abstract][Full Text] [Related]
16. Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).
Podzamczer D; Andrade-Villanueva J; Clotet B; Taylor S; Rockstroh JK; Reiss P; Domingo P; Gellermann HJ; de Rossi L; Cairns V; Soriano V
HIV Med; 2011 Jul; 12(6):374-82. PubMed ID: 21518220
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
[TBL] [Abstract][Full Text] [Related]
18. [From HAART to "smart": maximizing the advantages of lopinavir/ritonavir].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():68-9. PubMed ID: 15373055
[No Abstract] [Full Text] [Related]
19. 96-week CASTLE data show similar efficacy results.
AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043840
[No Abstract] [Full Text] [Related]
20. Should a protease inhibitor be standard of care for HIV postexposure prophylaxis?
McAllister J; Carr A
AIDS; 2011 Mar; 25(5):721-2. PubMed ID: 21368592
[No Abstract] [Full Text] [Related]
[Next] [New Search]